Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 31, Issue 3, 2011, Pages 337-344

  Grossberg, Sidney E ^a   Oger, Joel ^b   Grossberg, Leslie D ^a   Gehchan, Adel ^c,d   Klein, John P ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Biogen Idec Canada Inc   (Canada)

^d Baxter Corp   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; BIOASSAY; BLOOD LEVEL; BLOOD SAMPLING; CANADA; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SERUM; SINGLE DRUG DOSE; TREATMENT DURATION; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 79952301773     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0038     Document Type: Article

References (44)

1. Beck CA, Metz LM, Svenson LW, Patten SB. 2005. Regional variation of multiple sclerosis prevalence in Canada. Mult Scler 11:516-519. (Pubitemid 41387694)
2. Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P. 2004. Immunogenicity of interferon beta: Differences among products. J Neurol 251:1115-1124.
3. Boz C, Oger J, Gibbs E, Grossberg SE. 2007. Reduced effectiveness of long-term interferon-β treatment of relapses in neutralizing antibody-positive multiple sclerosis patients: A Canadian multiple sclerosis clinic-based study. Mult Scler 13:1127-1137. (Pubitemid 351541416)
4. Butler M. 2006. Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by mammalian cell systems. Cytotechnology 50:57-76.
5. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW. 2002. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507-1517. (Pubitemid 35387054)
6. Cohen BA, Oger J, Gagnon A, Giovannoni F. 2008. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 275:7-17.
7. Files JG, Hargrove D, Delute I, Cantillon M. 2007. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. J Interferon Cytokine Res 26:637-642. (Pubitemid 350194560)
8. Francis GS, Rice GPA, Alsop JC; for the PRISMS Study Group. 2005. Interferon β-1a in MS: Results following development of neutralizing antibodies in PRISMS. Neurology 65:48-55.
9. Gibbs E, Oger J. 2007. The IgG subclass-specificities of anti-IFNβ antibodies change with time and differ between the IFNβ products in relapsing remitting multiple sclerosis patients. J Immunol 190:146-150. (Pubitemid 47625609)
10. Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sorensen PS, Stubinski B. 2009. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 15:219-228.
11. Giovannoni G, Munschauer FE 3rd, Deisenhammer F. 2002. Neutralizing antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:465-469. (Pubitemid 35246792)
12. Gneiss C, Reindl M, Lutterotti A, Ehling R, Egg R, Khalil M, Berger T, Deisenhammer F. 2004. Interferon-beta: The neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 10:507-510. (Pubitemid 39207222)
13. Gneiss C, Tripp P, Reichartseder F, Egg R, Ehling R, Lutterotti A, Khalil M, Kuenz B, Mayringer I, Reindl M, Berger T, Deisenhammer F. 2006. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 12:731-737. (Pubitemid 46111764)
14. Goelz SE, Walt L. 2007. Development of neutralizing antibodies to intramuscular interferon beta-1a (Avonex). Mult Scler 13:S14-S20. (Pubitemid 46939514)
15. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC. 2007. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 68:977-984. (Pubitemid 46569129)
16. Grossberg SE, Kawade Y. 2006. The development and measurement of antibodies to interferon. In: Meager A, ed. The interferons: Characterization and application. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. pp 375-399.
17. Grossberg SE, Kawade Y, Grossberg LD. 2009. The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low anti-body levels. J Interferon Cytokine Res 29:93-104.
18. Grossberg SE, Kawade Y, Kohase M, Klein JP. 2001a. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: The tenfold reduction unit. J Interferon Cytokine Res 21:743-755. (Pubitemid 32955704)
19. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. 2001b. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 21:729-742. (Pubitemid 32955703)
20. Grossberg SE, Taylor JL, Siebenlist RE, Jameson P. 1986. Biological and immunological assays of human interferons. In: Rose NR, Friedman R, Fahey JL, eds. Manual of clinical immunology, 3rd ed. Washington, DC: ASM Publishing. pp 295-299.
21. Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. 2007. Neutralising antibodies to interferon beta in multiple sclerosis: Expert panel report. J Neurol 254:827-837. (Pubitemid 47222316)
22. Herndon RM, Rudick RA, Munschauer FE 3rd, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Coha SL, Genai C, Goodkin D, Toal M, Riester K. 2005. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 11:409-419. (Pubitemid 40984235)
23. Hesse D, Sellebjerg F, Sorensen PS. 2009. Absence of MxA induction by interferon b in patients with MS reflects complete loss of bioactivity. Neurology 73:372-377.
24. Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM. 2009. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Mult Scler 15:601-605.
25. Lallemand C, Mariete J-F, Erickson R, Grossberg SE, Roullet E, Lyon-Caen O, Lebon P, Tovey MG. 2008. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferonregulated reporter-gene. J Interferon Cytokine Res 28: 393-404. (Pubitemid 351929939)
26. Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC. 1989. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J Interferon Res 9 (Suppl 1):S51-S60.
27. O'Connor P, Devonshire V, Canadian Network of MS Clinics. 2008. The use of disease-modifying agents inmultiple sclerosis - by the Canadian Network of MS Clinics. Can J Neurol Sci 35:127-132.
28. Pachner AR, Brady J, Steiner I, Narayan K. 2008. Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients. J Neurol 255:1815-1817.
29. Pozzili C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C. 2002. Monthly corticosteroids decrease neutralizing antibodies to IFNb1b: A randomized trial in multiple sclerosis. J Neurol 249:50-56. (Pubitemid 34119023)
30. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. 2001. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628-1636.
31. Ravnborg M, Bendtzen K, Christensen O, Jensen PEH, Hesse D, Tovey M, Sorensen PS. 2009. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Mult Scler 15:323-328.
32. Rice GPA, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. 1999. The Evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon Beta 1b. Neurology 52:1277-1279. (Pubitemid 29177937)
33. Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch- Henriksen N, Skovgaard GL, Bendtzen K. 2000. Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Danish multiple sclerosis study group. Ann Neurol 48:706-712.
34. Rotstein DL, Mandani M, O'Conner PW. 2010. Increasing use of disease modifying drugs in Canada. Can J Neurol Sci 37:383-388.
35. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE 3rd, Cookfair DL, Simon JH, Jacobs LD, Multiple Sclerosis Collaborative Research Group (MSCRG). 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:1266-1272.
36. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15:641-649. (Pubitemid 28214960)
37. Sominanda A, Hillert J, Fogdell-Hahn A. 2008. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralizing antibody is titre-dependent. J Neurol Neurosurg Psychiatry 79:57-62.
38. Sominanda A, Hillert J, Fogdell-Hahn A. 2009. Neutralizing antibodies against interferon beta: Fluctuation is modest and titre dependent. Eur J Neurol 16:21-26.
39. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A. 2007. Interferon beta perparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13:208-214. (Pubitemid 46592773)
40. Sorensen PS. 2003. Antibodies to IFN-beta. Neurology 61(9 Suppl 5):S27-S28.
41. Sorensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C, EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis. 2005a. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: Report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12:817-827.
42. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group. 2005b. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65:33-39.
43. Yong VW, Chabot S, Stuve O, Williams G. 1998. Interferon beta in the treatment of multiple sclerosis: Mechanisms of action. Neurology 51:682-689. (Pubitemid 28449243)
44. Zarkou S, Carter JL, Welik KE, Demaerschalk BM, Wingerchuk DM. 2010. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic. Neurologist 16:212-214.